Objectives: There is a general belief that Graves’ orbitopathy (GO) is a “chronic” disease, namely that patients’ eyes do not return to how they were before GO appeared. Here, we investigate this issue from both the patient’s and the physician’s point of view. Study Design: We studied the disappearance of GO, regardless of treatment, in all consecutive patients with a GO history of at least 10 years who came for a follow-up visit over a period of 5 years. Patients underwent an ophthalmological examination and were asked to answer a questionnaire on self-perception related to GO. Results: We studied 99 consecutive patients with a GO duration ≥10 years. Between the first and the last observation, patients received several types of treatment for their thyroid disease and/or for GO. At the end of follow-up, GO was considered disappeared based on objective criteria in 8 patients (∼8%) and based on subjective criteria in 24 patients (∼24%). When we considered both subjective and objective criteria, only 2 patients (∼2%) had all criteria fulfilled and could be considered as GO-free. Conclusions: GO is a chronic disease in the vast majority of patients. Even after a very long time since its onset, complete disappearance is rare, although a minority of patients believe they do not have GO anymore and an even lower proportion do not have relevant GO signs. Our findings have obvious implications in patient management and counseling.

Keywords:
Graves’ orbitopathy, Graves’ disease, Thyroid, Autoimmunity
1.
Bahn RS: Graves’ ophthalmopathy. N Engl J Med 2010; 362: 726–738.
2.
Bartalena L: Diagnosis and management of Graves’ disease: a global overview. Nat Rev Endocrinol 2013; 9: 724–734.
3.
Bartalena L, Baldeschi L, Boboridis K, Eckstein A, Kahaly GJ, Marcocci C, Perros P, Salvi M, Wiersinga WM; European Group on Graves’ Orbitopathy (EUGOGO) European Group on Graves’ Orbitopathy (EUGOGO): The 2016 European Thyroid Association/European Group on Graves’ Orbitopathy Guidelines for the Management of Graves’ Orbitopathy. Eur Thyroid J 2016; 5: 9–26.
4.
Bartalena L, Masiello E, Magri F, Veronesi G, Bianconi E, Zerbini F, Gaiti M, Spreafico E, Gallo D, Premoli P, Piantanida E, Tanda ML, Ferrario M, Vitti P, Chiovato L: The phenotype of newly diagnosed Graves’ disease in Italy in recent years is milder than in the past: results of a large observational longitudinal study. J Endocrinol Invest 2016; 39: 1445–1451.
5.
Rundle FF, Wilson CW: Development and course of exophthalmos and ophthalmoplegia in Graves’ disease with special reference to the effect of thyroidectomy. Clin Sci 1945; 5: 177–194.
6.
Rundle FF: Management of exophthalmos and related ocular changes in Graves’ disease. Metabolism 1957; 6: 36–48.
7.
Perros P, Crombie AL, Kendall-Taylor P: Natural history of thyroid associated ophthalmopathy. Clin Endocrinol (Oxf) 1995; 42: 45–50.
8.
Tanda ML, Piantanida E, Liparulo L, Veronesi G, Lai A, Sassi L, Pariani N, Gallo D, Azzolini C, Ferrario M, Bartalena L: Prevalence and natural history of Graves’ orbitopathy in a large series of patients with newly diagnosed Graves’ hyperthyroidism seen at a single center. J Clin Endocrinol Metab 2013; 36: 444–449.
9.
Menconi F, Profilo MA, Leo M, Sisti E, Altea MA, Rocchi R, Latrofa F, Nardi M, Vitti P, Marcocci C, Marinò M: Spontaneous improvement of untreated mild Graves’ ophthalmopathy: Rundle’s curve revisited. Thyroid 2014; 24: 60–66.
10.
Menconi F, Leo M, Sabini E, Mautone T, Nardi M, Sainato A, Sellari-Franceschini S, Vitti P, Marcocci C, Marinò M: Natural history of Graves’ orbitopathy after treatment. Endocrine 2016, Epub ahead of print.
11.
Anagnostis P, Boboridis K, Adamidou F, Kita M: Natural course of mild Graves’ orbitopathy: is it a chronic remitting or a transient disease? J Endocrinol Invest 2017; 40: 257–261.
12.
Agapitos PJ, Hart IR: Long-term follow-up of ophthalmic Graves’ disease. CMAJ 1987; 15: 369–372.
13.
Teng CS, Yeo PP: Ophthalmic Graves’s disease: natural history and detailed thyroid function studies. Br Med J 1977; 1: 273–275.
14.
Mourits MP, Lombardo SH, van der Sluijs FA, Fenton S: Reliability of exophthalmos measurement and the exophthalmometry value distribution in a healthy Dutch population and in Graves’ patients. An exploratory study. Orbit 2004; 23: 161–168.
15.
Bilen H, Gullulu G, Akcay G: Exophthalmometric values in a normal Turkish population living in the northeastern part of Turkey. Thyroid 2007; 17: 525–528.
16.
Kashkouli MB, Nojomi M, Parvaresh MM, Sanjari MS, Modarres M, Noorani MM: Normal values of hertel exophthalmometry in children, teenagers, and adults from Tehran, Iran. Optom Vis Sci 2008; 85: 1012–1017.
17.
Beden U, Ozarslan Y, Oztürk HE, Sönmez B, Erkan D, Oge I: Exophthalmometry values of Turkish adult population and the effect of age, sex, refractive status, and Hertel base values on Hertel readings. Eur J Ophthalmol 2008; 18: 165–171.
18.
Chan W, Madge SN, Senaratne T, Senanayake S, Edussuriya K, Selva D, Casson RJ: Exophthalmometric values and their biometric correlates: The Kandy Eye Study. Clin Exp Ophthalmol 2009; 37: 496–502.
19.
Bartley GB, Fatourechi V, Kadrmas EF, Jacobsen SJ, Ilstrup DM, Garrity JA: Long-term follow-up of Graves ophthalmopathy in an incidence cohort. Ophthalmology 1996; 103: 958–962.
20.
Terwee C, Wakelkamp I, Tan S, Dekker F, Prummel MF, Wiersinga W: Long-term effects of Graves’ ophthalmopathy on health-related quality of life. Eur J Endocrinol 2002; 146: 751–757.
21.
Mourits MP, Prummel MF, Wiersinga WM, Koornneef L: Clinical activity score as a guide in the management of patients with Graves’ ophthalmopathy. Clin Endocrinol (Oxf) 1997; 47: 9–14.
22.
Marcocci C, Kahaly GJ, Krassas GE, Bartalena L, Prummel M, Stahl M, Altea MA, Nardi M, Pitz S, Boboridis K, Sivelli P, von Arx G, Mourits MP, Baldeschi L, Bencivelli W, Wiersinga W; European Group on Graves’ Orbitopathy: Selenium and the course of mild Graves’ orbitopathy. N Engl J Med 2011; 364: 1920–1931.
23.
Leo M, Bartalena L, Rotondo Dottore G, Piantanida E, Premoli P, Ionni I, Di Cera M, Masiello E, Sassi L, Tanda ML, Latrofa F, Vitti P, Marcocci C, Marinò M: Effects of selenium on short-term control of hyperthyroidism due to Graves’ disease treated with methimazole: results of a randomized clinical trial. J Endocrinol Invest 2017; 40: 281–287.
24.
Bartalena L, Veronesi G, Krassas GE, Wier-singa WM, Marcocci C, Marinò M, Salvi M, Daumerie C, Bournaud C, Stahl M, Sassi L, Azzolini C, Boboridis KG, Mourits MP, Soeters MR, Baldeschi L, Nardi M, Currò N, Boschi A, Bernard M, von Arx G, Perros P, Kahaly GJ; European Group on Graves’ Orbitopathy (EUGOGO): Does early response to intravenous glucocorticoids predict the final outcome in patients with moderate-to-severe and active Graves’ orbitopathy? J Endocrinol Invest 2017; 40: 547–553.
25.
Marinò M, Latrofa F, Menconi F, Chiovato L, Vitti P: An update on the medical treatment of Graves’ hyperthyroidism. J Endocrinol Invest 2014; 37: 1041–1048.
26.
Ware JE Jr, Sherbourne CD: The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30: 473–483.
27.
EuroQol Group: EuroQol – a new facility for the measurement of health-related quality of life. Health Policy 1990; 16: 199–208.
© 2017 European Thyroid Association. Published by S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.